CAI/History

Caris Life Sciences Inc (CAI) vs peers

Health Care

$35.82

Latest weekly close · Market cap $10.1B

CAI's EV/EBITDA is 55.9x, compared with 21.6x at the middle of 4 peers.

Peer group: Biotechnology. Updated .

CAI and Biotechnology, ranked by EV/EBITDA
StockEV/EBITDAOwn 5-year percentile
CAICaris Life Sciences Inc55.9×98
VRTXVertex Pharmaceuticals25.5×87
ABBVAbbVie22.7×89
AMGNAmgen20.5×97
REGNRegeneron Pharmaceuticals18.3×74
GILDGilead Sciencesn/mn/m, not ranked
MRNAModernan/mn/m, not ranked
NTRANatera Incn/mn/m, not ranked
RVMDRevolution Medicines Incn/mn/m, not ranked
Peer median21.6×
How to read this comparison

Up to eight covered companies in the same industry, largest market value first.

EV/EBITDA divides enterprise value (market value plus debt, minus cash) by EBITDA over the last twelve months. The peer median leaves out CAI and stocks without a reading.

Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its EV/EBITDA is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.

Different growth rates, margins and financial risks can explain different multiples. Stocks without positive EBITDA have no reading.

CAI versus the peer median

+159%

CAI
55.9×
Peer median
21.6×
Own 5-year median
36.9×
CAI EV/EBITDA historyCalculate CAI's implied price

Source: SEC company filings and weekly market prices. Multiples use the last twelve months of financial results. Updated .

How the valuation data is built